Conservest Capital Advisors Inc. Grows Holdings in VanEck Biotech ETF $BBH

Conservest Capital Advisors Inc. raised its holdings in shares of VanEck Biotech ETF (NASDAQ:BBH) by 22.9% in the 1st quarter, Holdings Channel reports. The firm owned 20,276 shares of the company’s stock after purchasing an additional 3,782 shares during the quarter. Conservest Capital Advisors Inc.’s holdings in VanEck Biotech ETF were worth $3,812,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in BBH. Jane Street Group LLC bought a new position in shares of VanEck Biotech ETF in the first quarter worth about $659,000. Raymond James Financial Inc. lifted its holdings in VanEck Biotech ETF by 245.9% during the 2nd quarter. Raymond James Financial Inc. now owns 67,940 shares of the company’s stock valued at $10,414,000 after buying an additional 48,297 shares in the last quarter. Bank of America Corp DE lifted its holdings in VanEck Biotech ETF by 17.7% during the 2nd quarter. Bank of America Corp DE now owns 52,466 shares of the company’s stock valued at $8,042,000 after buying an additional 7,898 shares in the last quarter. Corient Private Wealth LLC boosted its position in VanEck Biotech ETF by 63.5% in the 2nd quarter. Corient Private Wealth LLC now owns 13,290 shares of the company’s stock valued at $2,037,000 after buying an additional 5,160 shares during the period. Finally, Osaic Holdings Inc. boosted its position in VanEck Biotech ETF by 87.1% in the 2nd quarter. Osaic Holdings Inc. now owns 1,465 shares of the company’s stock valued at $225,000 after buying an additional 682 shares during the period. 32.05% of the stock is owned by hedge funds and other institutional investors.

VanEck Biotech ETF Stock Performance

Shares of BBH stock opened at $202.80 on Wednesday. The company’s 50-day simple moving average is $191.96 and its two-hundred day simple moving average is $191.69. VanEck Biotech ETF has a one year low of $154.75 and a one year high of $212.54.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.